Resumen
La enfermedad respiratoria exacerbada por aspirina comprende un conjunto de signos y síntomas que involucran principalmente la vía aérea superior e inferior posterior al consumo de inhibidores de la enzima ciclooxigenasa. Las reacciones adversas que se presentan no se consideran una alergia y son comunes a todos los antiinflamatorios no esteroideos, por lo que la reactividad cruzada entre estos es común. La descripción de tres casos clínicos con diferentes situaciones sirve para revisar aspectos clave de la enfermedad como la epidemiologia, fisiopatología, manifestaciones clínicas, diagnóstico y manejo. El adecuado diagnóstico y educación en el uso o eliminación de los diferentes AINE es fundamental, al igual que la disposición de opciones analgésicas alternativas, comprobadas mediante pruebas de provocación. El manejo de la enfermedad respiratoria exacerbada por aspirina incluye procedimientos quirúrgicos para el control de los pólipos nasales, tratamiento farmacológico para el control del asma y desensibilización con aspirina en individuos seleccionados.
Referencias
Sakalar EG, Muluk NB, Kar M, Cingi C. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol. 2017;274(3):1292-1300. DOI: 10.1007/s00405-016-4273-1
Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory diseas-new prime suspects. N Engl J Med. 2016;374(5):484-488. DOI: 10.1056/NEJMcibr1514013
Steinke JW, Negri J, Liu L, Payne SC, Borish L. Aspirin activation of eosinophils and mast cells: Implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol. 2014;193(1):41-47. DOI: 10.4049/jimmunol.1301753
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773-786. DOI: 10.1016/j.jaci.2006.07.024
Samter M, Beers R. Intolerance to aspirin. Clinical studies and consideration of its Pathogenesis. Ann Intern Med. 1968;68(5):975-983. DOI: 10.7326/0003-4819-68-5-975
Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017;139(3):764-766. DOI: 10.1016/j.jaci.2016.09.025
Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin NA. 2017;33(2):163-176. DOI: 10.1016/j.iac.2012.11.002
Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin- exacerbated respiratory disease: A practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172-174. DOI: 10.1016/S1081-1206(10)60692-8
Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017;5(3):537-545. DOI: 10.1016/j.jaip.2016.10.021
Jares EJ, Sánchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez M, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol. 2014;113(3):282-289. DOI: 10.1016/j.anai.2014.06.019
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-681. DOI: 10.1016/j.jaci.2014.08.020
Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070. DOI: 10.1016/j.jaip.2016.12.027
Vento SI, Ertama LO, Hytönen ML, Wolff CH, Malmberg CH. Nasal polyposis: Clinical course during 20 years. Ann Allergy Asthma Immunol. 2000;85(3):209-214. DOI: 10.1016/S1081-1206(10)62468-4
Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol. 1977;59(1):17-21. Disponible en: http://www.jacionline.org/article/0091-6749(77)90171-3/pdf
Cahill KN, Laidlaw TM. Pathogenesis of aspirin-induced reactions in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):681-691. DOI: 10.1016/j.iac.2016.06.005
Parker AR, Ayars AG, Altman MC, Henderson WR. Lipid mediators in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):749-763. DOI: 10.1016/j.iac.2016.06.009
Christie PE, Tagari P, Ford-hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects 1-3. Am Rev Respir Dis. 1990;143(5 Pt 1):1025-1029.
Hill J, Burnett T, Katial R. Mechanisms of benefit with aspirin therapy in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):735-747. DOI: 10.1016/j.iac.2016.06.011
Cowburn AS, Sladek K, Soja J, Adamek L, Lam K, Austen ST, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101(4):834-846. DOI: 10.1172/JCI620
Tanaka W, Tozzi CA, Reiss TF, Green SA, Malice MP. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax. 2004;59(2):100-104. DOI: 10.1136/thx.2004.006825
Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013;288(16):10967-10972. DOI: 10.1074/jbc.C113.453704
Bankova LG, Lai J, Yoshimoto E, Boyce JA, Austen KF, Kanaoka Y, et al. Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99. Proc Natl Acad Sci U S A. 2016;113(22):6242-6247. DOI: 10.1073/pnas.1605957113
Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001;98(6):1942-1949. DOI: 10.1182/blood.V98.6.1942
Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D2: A dominant mediator of aspirin exacerbated respiratory disease. J Allergy Clin Immunol. 2016;135(1):245-252. DOI: 10.1016/j.jaci.2014.07.031
Liu T, Kanaoka Y, Barrett NA, Feng C, Lai J, Boyce JA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. 2015;195(8):3537-3545. DOI: 10.4049/jimmunol.1500905
Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2017;137(5):1566-1576. DOI: 10.1016/j.jaci.2015.10.020
Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790-3798. DOI: 10.1182/blood-2011-10-384826
Mitsui C, Kajiwara K, Hayashi H, Ito J, Mita H, Ono E, et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(2):400-411. DOI: 10.1016/j.jaci.2015.05.041
Celik GE, Schroeder JT, Hamilton R, Saini S, Adkinson F. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2010;39(10):1522-1531. DOI: 10.1111/j.1365-2222.2009.03277.x
Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105(2):130-135. DOI: 10.1016/j.anai.2010.05.020
Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89(5):474-478. DOI: 10.1016/S1081-1206(10)62084-4
Graefe H, Roebke C, Schäfer D, Meyer JE. Aspirin sensitivity and chronic rhinosinusitis with polyps : a fatal combination. J Allergy (Cairo). 2012;2012(1):817910. DOI: 10.1155/2012/817910
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2017;124(3):428-433. DOI: 10.1016/j.jaci.2009.06.027
Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol. 2003;24(2):113-124. DOI: 10.1385/CRIAI:24:2:113
Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30(6):407-413. DOI: 10.2500/ajra.2016.30.4370
Schmidt JT, De-Bruïne FT, Van-Buchem MA Van, Sterk PJ, Rabe KF, Bel EH, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109(4):621-626. DOI: 10.1067/mai.2002.122458
Woessner KM. Update on aspirin-exacerbated respiratory disease. Curr Allergy Asthma Rep. 2017;17(1):2. DOI: 10.1007/s11882-017-0673-6
Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps , and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420-425. DOI: 10.1016/S1081-1206(10)60465-6
Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: Evaluation and management. Allergy Asthma Immunol Res. 2011;3(1):3-10. DOI: 10.4168/aair.2011.3.1.3
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62(10):1111-1118. DOI: 10.1111/j.1398-9995.2007.01409.x
Miller B, Mirakian R, Gane S, Larco J, Sannah AA, Darby Y, et al. Nasal lysine aspirin challenge in the diagnosis of aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2013;43(8):874-880. DOI: 10.1111/cea.12110
White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97(2):190-195. DOI: 10.1016/S1081-1206(10)60012-9
Herrera-Morales CI, Cardona-Villa R, Gómez-Henao C, Holguín-Gómez RM, Ramírez-Giraldo RH, Chinchilla-Mejía CF, et al. Safety of meloxicam oral provocation challenge in patients with NSAID reaction. World Allergy Organ J. 2015;8(Suppl 1):777. DOI: 10.1186/1939-4551-8-S1-A265.
Patrono C, FitzGerald GA. The coxibs, selective inhibitors of cyclooxygenasse-2. N Engl J Med. 2001;345(6):433-442. DOI: 10.1056/NEJM200108093450607
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568. DOI: 10.1073/pnas.96.13.7563
Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81-110. Disponible en: https://journals.library.ualberta.ca/jpps/index.php/jpps/article/viewFile/4128/3358
Walgama ES, Hwang PH. Aspirin-exacerbated respiratory disease. Otolaryngol Clin North Am. 2017;50(1):83-94. DOI: 10.1016/j.otc.2016.08.007
Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79(1):18-20:24-25.
Wentzel JL, Soler ZM, DeYoung K, Nguyen SA, Lohia S, Schlosser RJ. Leukotriene antagonists in nasal polyposis: A meta-analysis and systematic review. Am J Rhinol Allergy. 2013;27(6):482-489. DOI: 10.2500/ajra.2013.27.3976
Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):459-460. DOI: 10.1016/j.jaip.2015.01.012
Porcaro F, Di-Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. Pediatr Pulmonol. 2017;52(5):E26-E28. DOI: 10.1002/ppul.23615
Phillips-Angles E, Barranco P, Lluch-Bernal M, Dominguez-Ortega J, López-Carrasco V, Quirce S. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. J Allergy Clin Immunol Pract. 2017;5(3):842-845. DOI: 10.1016/j.jaip.2016.12.013.
Gevaert P, Calus L, Van-Zele T, Blomme K, De-Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116. DOI: 10.1016/j.jaci.2012.07.047
Zhang N, Holtappels G, Gevaert P, Patou J, Dhaliwal B, Gould H, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66(9):141-148. DOI: 10.1111/j.1398-9995.2010.02448.x
Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K, et al. Omalizumab reduces cysteinyl leukotriene and 9α11β prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585-1587. DOI: 10.1016/j.jaci.2015.09.034
Cardona-Villa R, Diez-Zuluaga LS, Ramírez-Giraldo RE, Sánchez-Caraballo JM. Desensibilización al ácido acetil-salicílico como tratamiento para la enfermedad respiratoria exacerbada por antiinflamatorios no esteroides. Iatreia (Medellín). 2014;27(3):299-308.
Cardona-Villa R, Ramírez RH, Reina Z, Escobar MF, Morales E. Alergia e intolerancia a antiinflamatorios no esteroides: desensibilización exitosa en tres casos y revisión de la literatura. Biomédica. 2009;29:181-190. Disponible en: http://www.scielo.org.co/pdf/bio/v29n2/v29n2a03.pdf
Cho K, Soudry E, Psaltis AJ, Nadeau KC, McGhee SA, Nayak JV, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):2-8. DOI: 10.1177/0194599814545750.
Cortellini G, Caruso C, Romano A. Aspirin challenge and desensitization: How, when and why. Curr Opin Allergy Clin Immunol. 2017;17(4):247-254. DOI: 10.1097/ACI.0000000000000374
Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180-186. DOI: 10.1067/mai.2003.7
Waldram JD, Simon RA. Performing aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):693-703. DOI: 10.1016/j.iac.2016.06.006
Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124(4):724-730. DOI: 10.1016/j.jaci.2009.07.031
Chen JR, Buchmiller BL, Khan DA. An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(6):926-931. DOI: 10.1016/j.jaip.2015.06.013
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2018 Revista Alergia México